Mr. Elad Bibi-Aviv reports

SEEGNAL INC. ANNOUNCES CLOSING OF FIRST TRANCHE AND UPSIZE AND EXTENSION OF PRIVATE PLACEMENT

Further to the news releases dated June 2, 2026, and July 21, 2026, Seegnal Inc. has closed the first tranche of its previously announced non-brokered private placement of units in the capital of the company. The company has upsized the private placement to up to $1.85-million and is expected to close the second tranche by Sept. 30, 2026.

The TSX Venture Exchange has approved an extension and upsize for the company to complete the non-brokered private placement for up to 6,607,143 units for gross proceeds of up to $1.85-million at a price of 28 cents per unit. As such, the second and final tranche of the upsized offering is expected to close on or about Sept. 30, 2026, subject to receipt of all regulatory approvals, including the final approval of the TSX-V and customary closing conditions.

Upon closing of tranche 1, the company has issued an aggregate of 1,486,500 units for gross proceeds of $416,220 at a price of 28 cents per unit. Each unit is composed of one common share in the capital of the company and one common share purchase warrant. Each warrant is exercisable to acquire one common share at a price of 50 cents for a period of 36 months. The proceeds from tranche 1 will be used by the company for general corporate and working capital purposes. No finders' fees were paid in connection with the closing of tranche 1. All securities issued under tranche 1 are subject to a hold period expiring four months and one day from the date of issuance.

Related-party disclosure

Certain insiders subscribed for an aggregate of 1,486,500 units in tranche 1, representing 100 per cent of the units sold in tranche 1. The insiders' participation in the upsized offering constitutes a related-party transaction as defined under Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions). Such participation by the insiders is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the securities to be acquired by the insiders, nor the consideration for the securities paid by such insiders exceeds 25 per cent of the company's market capitalization. The company did not file a material change report at least 21 days in advance of the closing of tranche 1 as the participation of such insiders in the upsized offering had not been confirmed at that time.

About Seegnal Inc.

Seegnal is an innovative health care technology company dedicated to reducing medication-related harm where care begins. The company's software-as-a-service-based clinical decision support platform is designed to help clinicians prescribe with greater precision by integrating patient-specific data at the point of care, including medications, laboratory results, renal function, allergies, age and other relevant risk factors. By delivering more targeted, context-aware medication alerts within existing clinical workflows, Seegnal aims to reduce alert fatigue, support safer prescribing and advance a more personalized standard of patient care. Seegnal's technology is deployed across health care settings and is used by more than 15,000 clinicians in daily practice.

We seek Safe Harbor.